drugset / Trial / NCT07282509
Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is an open-label, dose-escalation, and randomized controlled Phase Ib/II clinical study for second-line treatment in participants with advanced hepatocellular carcinoma (HCC). Its primary objective is to evaluate the safety, tolerability, pharmacokinetic profiles, and efficacy of transcatheter arterial infusion of HA131 combined with systemic therapy in the second-line treatment of participants with advanced HCC.
Timeline
- Start
- 2025-12-23
- Primary completion
- 2028-06-26
- Completion
- 2029-02-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enlonstobart | Monoclonal antibody | — | Intravenous |
| Subject | HA131 | Unknown | — | Other |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Background | Lenvatinib | Small molecule | — | Oral |